anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: immunology. SUBSTANCE: method deals with preparation of complex diagnostic kit representing the mixture of Brucella S- and R-antigens at 1-3 : 1-3 ratio, its contact with material under testing - blood serum - at the presence of test system and registration of reaction results. The most optimal ratios are those of S- and R-antigens being either 1:1 or 1:3. Application of the present method enables to simultaneously detect specific brucellosis antibodies to Brucella S- and R-variants without any decrease in specificity and sensitivity of reaction. EFFECT: higher efficiency of diagnostics. 5 cl, 11 ex, 11 tbl
Histopathologic examinations of primary central nervous system lymphoma (PCNSL) reveal concentric accumulation of lymphocytes in the perivascular area with fibrosis. However, the nature of this fibrosis in "stiff" PCNSL remains unclear. We have encountered some PCNSLs with hard masses as surgical findings. This study investigated the dense fibrous status and tumor microenvironment of PCNSLs with or without stiffness. We evaluated by silver-impregnation nine PCNSLs with stiffness and 26 PCNSLs without stiffness. Six of the nine stiff PCNSLs showed pathological features of prominent fibrosis characterized by aggregation of reticulin fibers, and collagen accumulations. Alpha-smooth muscle actin (αSMA)-positive spindle cells as a cancer-associated fibroblast, the populations of T lymphocytes, and macrophages were compared between fibrous and control PCNSLs. Fibrous PCNSLs included abundant αSMA-positive cells in both intra- and extra-tumor environments (5/6, 87% and 3/6, 50%, respectively). Conversely, only one out of the seven control PCNSL contained αSMA-positive cells in the intra-tumoral area. Furthermore, the presence of extra-tumoral αSMA-positive cells was associated with infiltration of T lymphocytes and macrophages. In conclusion, recognizing the presence of dense fibrosis in PCNSL can provide insights into the tumor microenvironment. These results may help stratify patients with PCNSL and improve immunotherapies for these patients.
The invention relates to the field of medicine and the pharmaceutical chemical industry. A pharmaceutical composition in suppository form for treating moderate to severe pain comprises the active principle nalbuphine hydrochloride and a suppository base. As the suppository base, the composition contains a hydrophilic emulsion base that includes binders, a poloxamer, a filler, an emulsifier, and propylene glycol and polyethylene oxide-400 as a solvent. The binders contained in the composition are preferably polyethylene oxide 4000 and polyethylene oxide 1500, and the poloxamer is poloxamer 188. The filler contained in the composition is preferably solid fat. Further, the emulsifier contained in the composition is preferably a complex emulsifier in the form of a blend of a type 1 emulsifier and a type 2 emulsifier. Proposed is a method for producing a pharmaceutical composition, according to which nalbuphine hydrochloride is dissolved in propylene glycol, the solution is mixed with a melted suppository base and homogenized; the liquid suppository mass is dosed into blister pockets and cooled.
BACKGROUND: Diabetes mellitus type 2 and pulmonary fibrosis have been found to be closely related in clinical practice. Diabetic pulmonary fibrosis (DPF) is a complication of diabetes mellitus, but its treatment has yet to be thoroughly investigated. Bu Yang Huan Wu Decoction (BYHWD) is a well-known traditional Chinese prescription that has shown great efficacy in treating pulmonary fibrosis with hypoglycemic and hypolipidemic effects.
METHODS: The active ingredients of BYHWD and the corresponding targets were retrieved from the Traditional Chinese Medicine Systematic Pharmacology Database (TCMSP) and SymMap2. Disease-related targets were obtained from the GeneCard, OMIM and CTD databases. GO enrichment and KEGG pathway enrichment were carried out using the DAVID database. AutoDock Vina software was employed to perform molecular docking. Molecular dynamics simulations of proteinligand complexes were conducted by Gromacs. Animal experiments were further performed to validate the effects of BYHWD on the selected core targets, markers of oxidative stress, serum lipids, blood glucose and pulmonary fibrosis.
RESULTS: A total of 84 active ingredients and 830 target genes were screened in BYHWD, among which 56 target genes intersected with DPF-related targets. Network pharmacological analysis revealed that the active ingredients can regulate target genes such as IL-6, TNF-α, VEGFA and CASP3, mainly through AGE-RAGE signaling pathway, HIF-1 signaling pathway and TNF signaling pathway. Molecular docking and molecular dynamics simulations suggested that IL6-astragaloside IV, IL6-baicalein, TNFα-astragaloside IV, and TNFα-baicalein docking complexes could bind stably. Animal experiments showed that BYHWD could reduce the expression of core targets such as VEGFA, CASP3, IL-6 and TNF-α. In addition, BYHWD could reduce blood glucose, lipid, and MDA levels in DPF while increasing the activities of SOD, CAT and GSH-Px. BYHWD attenuated the expression of HYP and collagen I, mitigating pathological damage and collagen deposition within lung tissue.
CONCLUSIONS: BYHWD modulates lipid metabolism disorders and oxidative stress by targeting the core targets of IL6, TNF-α, VEGFA and CASP3 through the AGE-RAGE signaling pathway, making it a potential therapy for DPF.
Heart disease, or cardiovascular disease, refers to a range of diseases including coronary artery disease, heart attack, heart failure, high blood pressure, and stroke. These diseases are all related to problems with the heart and blood vessels, and collectively are the leading cause of death in the United States. Heart attacks or coronary artery disease sometimes have warning signs, but both can occur without warning. Approximately half of all heart attacks are fatal. Forty percent of all deaths in the United States are the result of heart disease.

Certain factors can predict whether people get heart disease. Some of these factors, like biological sex or genes inherited from a person's family, cannot be changed, but many others can. Not smoking, eating well, exercising regularly, and maintaining a healthy weight are some of the things people can do to lower their risk of heart disease. This study will develop and then test an Internet-based program that teaches people about heart health and supports them in changing behaviors that put them at risk for heart disease.

This study will be divided into two phases. In the first phase, researchers will create the Heart Healthy program, show it to focus groups, and try to improve it based on their comments. The goals of the program are to educate users in the fundamentals of heart health and risk factors for heart disease and to provide a system for starting and sustaining lifestyle changes that reduce risk of heart disease. The program will be designed for employee use in a workplace, and a tool kit will be developed for managers to supplement the employee program. The prototype will include modified segments from existing Web-based programs created by a non-profit organization, the ISA Group. The design of the program will be guided by feedback from employees and managers who use it and from experts in cardiology and epidemiology.

In the second phase, the program will be tested in a work site. Employees at risk for heart disease will be recruited and randomly assigned to receive either the Healthy Heart program or treatment as usual. Before and after the intervention, participants will be assessed on knowledge gained, attitudes changed, alterations in health behavior, and reductions in cardiovascular risk. Managers who receive the supplementary program will be tested in knowledge gained and plans for policy or procedural changes. The ultimate goal of this phase is to fully develop the Healthy Heart program for use in industry and health care settings.
The aim of this study is to assess in vivo intracoronary anatomy using intravascular ultrasound and optical coherence tomography and assess the efficacy and safety of new generation fully bioresorbable vascular scaffolds in a systemic autoimmune and coronary heart disease patient population.

The following four well defined systemic autoimmune entities are linked to increased cardiovascular risk: rheumatoid arthritis, mixed connective tissue disease, systemic sclerosis and systemic lupus erythematosus. One of the main causes of death in systemic autoimmune subjects is cardiovascular disease. In-vivo intracoronary anatomy and pathology regarding systemic autoimmune diseases is unknown. Furthermore, all forms of revascularization in such patients yield sub-optimal results, with poor outcomes using even the most modern drug eluting metallic stents. This may be linked to a long term exaggerated chronic inflammation response to the metallic components. Thus, fully bioresorbable vascular scaffolds may prove more efficacious in systemic autoimmune subjects.
The present invention relates to a vector containing a nucleic acid sequence coding for a protein and at least one nuclear sequence that is to be transported. The vector is capable of expressing the transport protein in a host cell. The transport protein has at least one binding point for the vector and can ensure intercellular transport of said vector. The invention also relates to the use of said vector to increase the transfection efficacy of nucleic acids. The present invention specifically relates to a novel system that preferably combines both biological functions specific to said nucleic acids, i.e. replication (multiplication) and  intercellular transport (propagation), in a novel manner. This results in a system that can infiltrate genetic information in tissues and organisms in a virus-like manner and re-transmit it.
BACKGROUND: Long covid (post covid-19 condition) is a complex condition with diverse manifestations, uncertain prognosis and wide variation in current approaches to management. There have been calls for formal quality standards to reduce a so-called "postcode lottery" of care. The original aim of this study-to examine the nature of quality in long covid care and reduce unwarranted variation in services-evolved to focus on examining the reasons why standardizing care was so challenging in this condition.
METHODS: In 2021-2023, we ran a quality improvement collaborative across 10 UK sites. The dataset reported here was mostly but not entirely qualitative. It included data on the origins and current context of each clinic, interviews with staff and patients, and ethnographic observations at 13 clinics (50 consultations) and 45 multidisciplinary team (MDT) meetings (244 patient cases). Data collection and analysis were informed by relevant lenses from clinical care (e.g. evidence-based guidelines), improvement science (e.g. quality improvement cycles) and philosophy of knowledge.
RESULTS: Participating clinics made progress towards standardizing assessment and management in some topics; some variation remained but this could usually be explained. Clinics had different histories and path dependencies, occupied a different place in their healthcare ecosystem and served a varied caseload including a high proportion of patients with comorbidities. A key mechanism for achieving high-quality long covid care was when local MDTs deliberated on unusual, complex or challenging cases for which evidence-based guidelines provided no easy answers. In such cases, collective learning occurred through idiographic (case-based) reasoning, in which practitioners build lessons from the particular to the general. This contrasts with the nomothetic reasoning implicit in evidence-based guidelines, in which reasoning is assumed to go from the general (e.g. findings of clinical trials) to the particular (management of individual patients).
CONCLUSION: Not all variation in long covid services is unwarranted. Largely because long covid's manifestations are so varied and comorbidities common, generic "evidence-based" standards require much individual adaptation. In this complex condition, quality improvement resources may be productively spent supporting MDTs to optimise their case-based learning through interdisciplinary discussion. Quality assessment of a long covid service should include review of a sample of individual cases to assess how guidelines have been interpreted and personalized to meet patients' unique needs.
STUDY REGISTRATION: NCT05057260, ISRCTN15022307.
The proposed study is a low-risk, randomized control trial to assess the efficacy of the HOPE (Harnessing Online Peer Education) intervention, an evidenced-based peer-led social media/online community intervention (e.g., Facebook Groups), to increase self-reported requests for medications for opioid use disorder (MOUD) among patients with moderate to severe opioid use disorder (OUD). Participants will be recruited using a variety of recruitment methods including social media sites (e.g., Facebook), referral by physicians, medical records, research study websites (e.g., UCIMC Clinical Trials website), and study flyers disseminated at various venues, including clinics, group meetings, and shelters. Once enrolled, participants will be randomly assigned to an intervention or control group. Intervention group participants will be invited to join a private and hidden (unable to be viewed or searched for by others) group on Facebook, with approximately 6 peer leaders included in the group. Those in the control group will be invited into a Facebook group, but without peer leaders. The intervention will last 12 weeks. Study measures will be collected at the beginning of the study (baseline), after the completion of the intervention (3 months), with follow up surveys at 6 and 12 months after the study.
Frailty is a wasting syndrome of old age that leaves a person vulnerable to falls, functional decline, morbidity and mortality. Reducing the severity of frailty will provide large benefits for individuals, their families and for the society. It is assumed that early intervention with frail people will improve quality of life and reduce the costs of care. This trial is testing the frailty intervention with herbal medicine. If this frailty intervention is shown to be effective, there are major potential benefits to the frail older population generally in terms of decreased disability. The interventions being examined are readily transferable to routine clinical practice and can potentially be applied routinely in aged care services.
The present invention discloses medicine for treating the necrosis of bones because of ischemia, delayed fracture union and the disconnection of bones. The present invention is prepared from the following medicine ingredients (wt%): 90 portions of the carda part of radix angelicae sinensis root, 60 portions of ground beetle, 90 portions of prepared native copper, 20 portions of draconis resin, 90 portions of earthworm, 50 portions of prepared pangolin scales, 20 portions of drynaria, 20 portions of ephedra herb, 6 portions of prepared nux vomica, 90 portions of largeleaf gentian root, 90 portions of clematis root, 120 portions of himalayan teasel root and 120 portions of astragalus root. The ingredients are prepared into a pill by a conventional method. The present invention adopts natural traditional Chinese medicine as raw materials. The ingredients accord with the regulation of pharmaceutical administration, use the combined action of traditional Chinese medicine and have the efficacy of invigorating qi, promoting circulation of blood, strengthening bone, continuing tendons, stimulating circulation to end stasis, dredging channels, expelling wind, eliminating dampness, tonifying the liver and the kidney, tonifying energy and benefiting marrow. The present invention has treatment and rehabilitation efficacy for the necrosis of the bone because of ischemia, delayed fracture union and the disconnection of the bone. The present invention has no toxin and harmlessness for human bodies. After cases of clinical observation and selection for many years, recovery patients reach 500 cases. A total effective rate reaches over 98 %.
Isomalto-oligosaccharide (IMO) is a mixture of natural resistant carbohydrates consisting of short-chains of glucose molecules. IMO is made by enzymatic conversion of starch and uses as a health food ingredient with health benefits of a low calorie sweetener, prebiotic and dietary fiber. IMO have been ingested by humans for last many centuries as it is naturally found in rice miso, sake and soy sauce. IMO already got approval from FDA (GRAS) and from Health Canada.

There are number of published studies (in humans and animals) regarding the health benefits of IMO as an effective prebiotic, and its role in improving overall human gastric health. Studies also showed that IMO have found to be most tolerable with least adverse effects compared to other short-chain resistant oligosaccharides. Current clinical studies are conducted to verify the above given health benefits in BioNeutra's manufactured VitaSugar/VitaFiber-IMO products which including quantitative analysis of Bifidobacteria spp., Lactic acid bacteria group and clostridium spp. The production of short-chain fatty-acids (SCFA) and effect on blood glucose level are also analyzed in addition to the dose tolerance in term of lower and upper permissible dosage with resultant adverse effects if any are also observed.
The injured digital nerve is exposed during a surgical intervention and sutured with 2 or three epineural sutures 8.0 or 9.0 synthetic monofilament non-resorbable suture. Postoperative treatment includes 3 weeks in a plaster cast followed by rehabilitation.
PURPOSE: Candida auris, a multidrug-resistant yeast, poses significant challenges in healthcare settings due to its ability to form biofilms and resistance to common disinfectants. Understanding its susceptibility to biocides used in hospital disinfection practices is crucial for infection control. We investigated the biocide sensitivity of eight clinical C. auris strains from different patients and one reference strain (CDC B11903) using the biocide activity tests.
METHODS: Species identification was confirmed through MALDI-TOF MS, while clade differentiation and phylogenetic classification were determined via whole-genome sequencing. Biofilm formation was assessed using the MTT assay. Antifungal susceptibilities were tested according to CLSI standards. The effectiveness of biocides, including chlorine, chlorhexidine, and benzalkonium chloride, was evaluated through broth microdilution following CLSI standards and quantitative suspension and carrier tests, following EN standards.
RESULTS: All clinical strains were identified as clade 1, and the reference strain as clade 4, with all exhibiting biofilm formation. Clade 1 strains showed resistance to fluconazole, with MIC values ranging from 8 to 32 µg/ml, while being susceptible to other antifungals. Broth microdilution MIC assays for biocides demonstrated that all strains exhibited resistance to benzalkonium chloride. Chlorine and chlorhexidine showed variable efficacy, dependent on concentration and environmental cleanliness. Alcohol-based hand sanitizers demonstrated effectiveness against C. auris from the first minute of application.
CONCLUSION: The study highlights the variable susceptibility of C.auris to different biocides, underscoring the challenge in eradicating this pathogen from healthcare environments. Our findings advocate for the careful selection of disinfectants in hospital settings, emphasizing the need for high-concentration chlorine and chlorhexidine solutions to combat C. auris, even in especially clean environments.
Following the submission of tumor tissue for the FoundationOne® companion diagnostic (F1CDx) test, participants with tumor type MSI-H and/or tTMB \>=10 mut/mb will be assigned to this cohort. Twenty participants will be enrolled initially. Once twenty participants are enrolled, the cohort may be expanded if a positive signal is shown. Participants in this study cohort will commence treatment as specified on Day 1 of each cycle.
A randomized, single-blind human intervention study involving 22 healthy male volunteers was designed to investigate the acute effects of ginger drink consumption on risk markers of cardiovascular disease (CVD). The primary outcome measure is reduction in blood pressure while the secondary outcome measures are improvement in flow mediated dilatation (FMD) and changes in plasma biochemical profile parameters related to CVD. Participants were given 300 ml of ginger extract or water (placebo) with breakfast, followed by a lunch at 2 hours on two visits separated by 2 weeks. Blood and urine samples were collected at regular intervals as well as blood pressure measurement done during the two visits. Vascular function was measured by flow mediated dilatation (FMD) and pulse wave velocity (PWV) at baseline, 2 and 4 hours after the the consumption of the study drink and placebo. The blood and urine samples were analysed for changes in lipid profile and other markers of CVD.
The invention discloses a medicine for treating hypertension, which is an over-the-counter medicine for treating circulatory system diseases. It can be used for treating essential hypertension. The medicine of the present invention is prepared with 9 kinds of Chinese medicinal materials, including gynostemma pentaphylla, chrysanthemum, etc. and through conventional process, and may be prepared into film coated tablet, hard capsule or sugar-free granule for oral taking. The product has effects in calming liver, suppressing yang hyperactivity, cooling blood, nourishing yin, and tonifying liver and kidney, and can regulate liver, kidney, heart, brain, and viscera, so as to reduce blood pressure. Prevent or reduce the fatality rate or disability rate caused by cardiovascular complications, correct cardiovascular risk factors, improve the life quality of patients and solve the problem that no specific medicine is available for treating hypertension at present.
A capsule for encapsulating implantable cells for improving the detectability of electrical signals generated by the cells is provided. The capsule includes a low-conductivity (high electrical resistance) membrane and a semi-permeable (low electrical resistance) membrane. The low-conductivity membrane seals around the circumference of the cell mass between the electrical poles of the capsule, and further extends for increasing the electrical resistance between the poles. The semi-permeable membrane enables nutrients and waste materials to flow to and from the cell mass. The semi-permeable membrane encloses at least one of the poles of the cell mass, and cooperates with the low-conductivity membrane to completely enclose the cell mass. The low-conductivity membrane may enclose one of the poles, if desired. Electrodes are used to detect the electrical signals from the cell mass. Various methods of making the capsule are disclosed.
The invention belongs to the technical field of biological medicines, and relates to application of pellitorine in preparation of an anxiolytic medicament. The wall grass alkali can increase the exploring behavior and spontaneous activity of the mice in a new environment and reduce the tension. The total number of arm entries and the percentage of arm entry time of mice in the elevated plus maze experiment were both increased and the percentage of arm entry time of closed arms was decreased for the diaphanous. After the wall grass alkali is dried, the number of times that the mice enter the open box is increased. After the wall grass alkali is dried, the MDA content of the hippocampal tissue of the mice is reduced, and the activities of SOD and GSH-Px are increased. The wall grass alkali can reduce the inhibition of oxidative stress of the mouse hippocampal tissue induced by CRS. After the wall grass alkali is dried, the expression of the mouse hippocampal tissue Bcl-2 is increased, and the expression of Bax is reduced. The wall grass alkali can inhibit CRS-induced apoptosis of mouse hippocampal tissue.